Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4006 Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

Introduction: Thymic neuroendocrine neoplasms (T-NENs) are rare mediastinal malignancies that lack established treatment guidelines. While the Capecitabine and Temozolomide (CapTem) regimen has demonstrated significant efficacy in patients with pancreatic NENs, its applicability and effectiveness in treating T-NENs remain underexplored.

Conference:

Presenting Author: Liu M

Authors: Liu M, Yan X, Lin X, Chen L, Wang Y,

Keywords: Capecitabine plus Temozolomide, Thymic Neuroendocrine Neoplasm, CapTem, T-NEN,

#1367 Thymic Neuroendocrine Neoplasia: Therapy with Everolimus

Introduction: Due to the low incidence of 0.02/100 000 no established medical therapy for thymic neuroendocrine neoplasia (t-NEN) exists.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lang M, Anamaterou C,

Keywords: thymus neuroendocrine neoplasia, thymic carcinoid, everolimus, targeted therapy, mTOR inhibitor, MEN1,

#417 CK19 Expression in A?TH-Producing Extrapituitary Neuroendocrine Neoplasms is a Negative Prognostic Factor

Introduction: Defining localization and potential ?CTH-producing extrapituitary neuroendocrine neoplasms (ACTH-epNEN) is important for clinical practice.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Gurevich L, Voronkova I, Marova E, Korsakova N, Britvin T,

Keywords: ?C?H-producing neuroendocrine neoplasms, IHC, CK19 expression, prognosis,